SecBot SecBot
6-K ·Filed Aug 18, 2026

GSK

GSK plc
NEUTRAL
Impact 1/10
Horizonimmediate Processed3mo ago SEC0001654954-26-007718
Notable filing: 6-K
Actionable Insight • Neutral

Routine administrative filing with zero trading signal. No action warranted; monitor upcoming earnings or pipeline catalysts for GSK's next material move.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$51.15
T+0 close · Aug 18, 2026 · via day close
Latest settled
−1.08%
T+60 · $50.60
Vs SPY
−0.08%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 18 $51.15entry
  2. T+1 · 3mo ago +3.38%α +3.17% · $52.88
  3. T+5 · 3mo ago +1.80%α +2.00% · $52.07
  4. T+20 · 2mo ago −1.68%α +0.06% · $50.29
  5. T+60 · 6d ago −1.08%α −0.08% · $50.60
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

GSK filed a Form 6-K disclosing routine dividend reinvestment transactions by three PDMRs (Dr. Hal Barron, James Ford, and Maya Martinez-Davis) in their Executive Supplemental Savings Plan and 401(k) accounts. These are notional, plan-level acquisitions totaling approximately 2,489 ADSs at $49.52 each, entirely mechanical and administrative in nature, with no discretionary insider signal.

Key Facts

  • Dr. Hal Barron (Non-Executive Director) acquired 2,279.563 notional ADS at $49.52 via supplemental plan dividend reinvestment.
  • James Ford (SVP & Group General Counsel) acquired 53.89 notional ADS at $49.52 via supplemental plan dividend reinvestment.
  • Maya Martinez-Davis (President, US) acquired 82.133 notional ADS at $49.52 via supplemental plan dividend reinvestment.
  • Dr. Hal Barron also acquired 73 ADS at $49.52 via 401(k) dividend reinvestment.
  • All transactions occurred on 2026-08-14 on the NYSE and are plan-driven, not open-market discretionary buys.

Financial Impact

Total notional acquisition ~$123,300 at $49.52/share, immaterial for a $100B+ market cap company.

Risk Factors

  • No material risks identified from this filing.

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
44% bullish (32 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001654954-26-007718
Document: 0001654954-26-007718-index-headers.html0001654954-26-007718
Document: 0001654954-26-007718-index.html0001654954-26-007718
Document: 0001654954-26-007718.txt0001654954-26-007718

US Market Status

Market Closed · Opens Wed (11h 38m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 18, 2026